Market Outlook

By 2035, the U.S. AI-Enabled Cardiovascular Devices Market is projected to reach approximately USD 34.85 billion, expanding at a CAGR of 21.80% during the forecast period from 2026 to 2035. The market was valued at USD 4.85 billion in 2025, following historical expansion from USD 2.28 billion in 2021 to USD 2.72 billion in 2022, USD 3.27 billion in 2023, and USD 3.98 billion in 2024. Values in this report are expressed in USD billions. The forecast reflects revenue attributable to FDA-regulated cardiovascular devices with embedded artificial intelligence, stand-alone software as a medical device used with cardiovascular equipment, device-linked cloud analytics, AI-enabled monitoring subscriptions, and the AI-attributable portion of capital systems and service contracts. General-purpose electronic health record analytics, non-regulated wellness applications, and AI used solely for administrative functions are excluded.

The market is advancing from isolated algorithm deployment toward integrated cardiovascular intelligence platforms that operate across screening, diagnosis, intervention, monitoring, and longitudinal disease management. U.S. providers are applying AI to electrocardiography, echocardiography, cardiac CT, cardiac MRI, intravascular imaging, ambulatory rhythm monitoring, implantable device surveillance, hemodynamic prediction, structural heart planning, and cath lab workflow. This expansion is not driven by software novelty alone. Adoption is strongest where an AI-enabled device can identify disease earlier, reduce manual interpretation time, increase diagnostic consistency, prioritize urgent studies, improve procedural planning, or convert an existing diagnostic test into a reimbursable higher-value assessment.

The clinical need is substantial. Cardiovascular disease caused 919,032 deaths in the United States in 2023, representing approximately one in every three deaths, while a cardiovascular death occurs about every 34 seconds. Nearly 6.7 million U.S. adults live with heart failure, and the atrial fibrillation population is projected to reach approximately 12.1 million by 2050. The American Heart Association further estimates that more than 184 million U.S. adults could have some form of cardiovascular disease, including hypertension, by 2050, with related direct and indirect costs approaching USD 1.8 trillion. These conditions create a large addressable pool for AI-enabled detection, image quantification, risk prediction, remote surveillance, and treatment guidance.

Market acceleration is also supported by regulatory normalization. By early 2025, the U.S. Food and Drug Administration had authorized more than 1,000 AI-enabled medical devices across clinical specialties, and cardiovascular use cases represented one of the most active categories after radiology. The FDA’s 2025 lifecycle guidance for AI-enabled device software functions increased expectations around training data quality, subgroup performance, transparency, change management, cybersecurity, and post-market monitoring. For established manufacturers, these requirements favor companies with deep clinical evidence, quality systems, and installed-base access. For specialized innovators, they create a clearer commercialization pathway but raise the cost of maintaining algorithms after launch.

Hospital purchasing behavior is shifting accordingly. Cardiovascular service lines are evaluating AI-enabled devices through total episode economics rather than algorithm accuracy in isolation. The strongest procurement cases link clinical performance to measurable operational outcomes such as shorter reading queues, fewer repeat scans, earlier referral, improved cath lab utilization, lower avoidable admissions, more efficient remote monitoring, or better capture of reimbursable services. As the U.S. hospital system manages more than 35.6 million annual admissions across approximately 907,000 staffed beds, scalable automation that expands specialist capacity is becoming strategically important. The market therefore favors solutions that fit existing equipment, integrate with PACS and EHR environments, provide actionable outputs inside clinician workflow, and demonstrate value at the health-system level.

Introduction

According to the U.S. AI-Enabled Cardiovascular Devices Market Report, artificial intelligence is becoming a functional layer across the cardiovascular device value chain rather than a separate technology category. AI-enabled cardiovascular devices include diagnostic systems that automate image and signal interpretation, monitoring devices that detect clinically relevant patterns, procedural systems that support navigation and device selection, implantable technologies that prioritize alerts, and connected platforms that convert continuous physiologic data into clinician-ready decisions. The market includes both hardware-led and software-led business models, with revenue generated through capital equipment, per-procedure fees, enterprise licenses, subscriptions, disposable utilization, service contracts, and reimbursement-linked clinical assessments.

The U.S. market is especially attractive because it combines a large cardiovascular disease burden with high imaging and procedure intensity, mature specialist networks, advanced hospital infrastructure, and a regulatory framework that recognizes software as a medical device. The country also has a dense concentration of academic medical centers, cardiovascular clinical trial sites, medtech manufacturers, cloud infrastructure companies, and health systems capable of validating new algorithms at scale. These conditions make the United States the primary commercialization market for AI-enabled cardiac imaging, predictive ECG, ambulatory monitoring, and procedure-guidance technologies.

The market’s value pool is distributed across several clinical workflows. In noninvasive cardiology, AI can quantify ventricular function, chamber dimensions, strain, valve disease, coronary plaque, perfusion, calcium, and structural abnormalities. In electrophysiology, algorithms improve arrhythmia detection, reduce false-positive alerts, prioritize implantable monitor transmissions, and assist rhythm classification. In interventional cardiology, AI supports intravascular image interpretation, lesion assessment, stent sizing, coronary physiology, and treatment planning. In heart failure, predictive models combine device signals, ECG patterns, acoustic biomarkers, weight, blood pressure, and hemodynamic data to identify decompensation risk earlier. Each workflow has different purchasing authority, reimbursement logic, data integration requirements, and evidence thresholds.

A central feature of this market is the distinction between clinical performance and commercial usability. Many algorithms can achieve strong retrospective accuracy, but U.S. hospitals require prospective evidence, interoperability, cybersecurity, implementation support, physician acceptance, and a credible path to reimbursement or productivity improvement. Products that create additional alerts without reducing workload may struggle despite technically strong performance. In contrast, systems that automate measurements, suppress low-value notifications, surface the highest-risk patients, and document time savings can generate faster adoption. The commercial winners will therefore be those that pair validated algorithms with disciplined workflow engineering.

The forecast assumes a continued transition from single-purpose AI applications to multi-algorithm cardiovascular platforms. Imaging manufacturers are embedding AI into scanners and workstations; monitoring companies are layering algorithms across large longitudinal datasets; cardiovascular software companies are integrating with enterprise reporting; and device manufacturers are using AI to differentiate implants, catheters, and procedural systems. By 2035, AI will increasingly be purchased as part of a cardiovascular platform contract rather than as a stand-alone experiment. This will expand market value while also increasing consolidation pressure, as hospitals prefer fewer vendors with broader integration, stronger support, and defensible clinical evidence.

Key Market Drivers: What’s Fueling the U.S. AI-Enabled Cardiovascular Devices Market Boom?

The first major driver is the scale and complexity of cardiovascular disease in the United States. Coronary artery disease, atrial fibrillation, heart failure, valvular disease, cardiomyopathy, hypertension, and peripheral vascular disease create high volumes of diagnostic tests and longitudinal monitoring encounters. AI-enabled devices are particularly valuable in conditions where disease is underdiagnosed, symptoms are nonspecific, or deterioration occurs between office visits. Predictive ECG algorithms for low ejection fraction or future atrial fibrillation, automated echocardiographic measurements, and continuous rhythm analytics expand the clinical value of tests that are already embedded in routine care.

A second driver is the shortage of specialist time relative to data growth. Cardiovascular care generates large volumes of ECG traces, echocardiography loops, CT datasets, MRI sequences, implantable-device transmissions, and wearable sensor streams. Manual review does not scale at the same rate. AI-enabled triage, quantification, and prioritization allow cardiologists, sonographers, radiologists, electrophysiology teams, and device clinics to focus on the cases most likely to require intervention. This capacity benefit is becoming more important as health systems face labor inflation, vacancy pressure, burnout, and uneven access to subspecialists outside major metropolitan areas.

A third driver is reimbursement maturation. The U.S. payment environment increasingly recognizes assistive algorithmic assessments, remote physiologic monitoring, ambulatory cardiac monitoring, advanced coronary CT analysis, and device-based follow-up. Separate hospital outpatient payment for certain assistive algorithmic ECG assessments beginning in 2025 demonstrated that AI can move from an unfunded workflow tool to a billable clinical service. Coverage gains for AI-assisted coronary CT analysis have similarly improved the business case for adoption. Reimbursement remains fragmented, but each new payment pathway reduces commercialization risk and encourages providers to standardize the technology.

A fourth driver is the expansion of connected cardiac monitoring. Patch-based ECG, mobile cardiac telemetry, implantable loop recorders, connected pacemakers and defibrillators, smart stethoscopes, home blood pressure devices, and hemodynamic sensors are creating continuous data streams that require algorithmic filtering. AI improves the economics of these devices by reducing false positives, prioritizing high-risk events, and enabling larger patient panels per technician or nurse. Monitoring businesses also produce recurring revenue, making them strategically attractive to both device manufacturers and health systems seeking longitudinal engagement.

A fifth driver is the shift toward earlier cardiovascular disease identification. U.S. care has historically concentrated resources after symptoms or acute events occur. AI-enabled devices support a different model by detecting subclinical disease from routine ECGs, limited echocardiography, incidental CT scans, digital auscultation, and longitudinal sensor patterns. This creates opportunities in primary care, emergency departments, oncology cardio-toxicity monitoring, preoperative assessment, and population health. Earlier detection can expand downstream demand for confirmatory imaging, specialist consultation, preventive therapy, and interventional treatment, making AI strategically relevant across the entire cardiovascular service line.

A sixth driver is hospital capital procurement and platform standardization. Large integrated delivery networks increasingly negotiate cardiovascular technology across multiple facilities. An AI-enabled platform can be favored when it improves utilization of existing scanners, reduces variability among sites, supports remote reading, and creates standardized measurements for quality reporting. Vendors with broad installed bases can distribute AI through software upgrades and service agreements, while specialized companies can gain access through OEM partnerships and enterprise integrations. Procurement committees are therefore evaluating not only algorithm performance but also deployment speed, data governance, vendor stability, and the ability to scale across diverse hospital environments.

A seventh driver is the need to improve procedure economics. Structural heart, electrophysiology, complex PCI, and heart failure programs are clinically sophisticated but operationally demanding. AI-assisted imaging and planning can reduce measurement variability, improve patient selection, identify anatomic constraints, and support device sizing. In the cath lab, automated intravascular imaging interpretation and physiology can help standardize decisions and reduce cognitive burden. In electrophysiology, smarter mapping and signal analysis may improve procedure consistency. Technologies that shorten procedure time, reduce complications, or enable more cases per lab day can justify premium pricing even when direct reimbursement for the AI component is limited.

An eighth driver is regulatory clarity combined with stronger evidence expectations. The FDA’s AI lifecycle framework, predetermined change control plan principles, good machine learning practice, cybersecurity requirements, and real-world performance focus are creating a more structured market. This benefits buyers because it supports transparency and post-market accountability. It also rewards manufacturers that can validate performance across age, sex, race, comorbidity, device type, and site of care. As hospitals become more sensitive to algorithmic bias and model drift, robust evidence and governance will increasingly determine whether an AI-enabled cardiovascular device reaches enterprise-scale use.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. AI-enabled cardiovascular devices market is moving from automated measurement toward clinically consequential prediction. Early products primarily reduced manual image segmentation or rhythm review. Newer systems identify latent signals that are difficult for clinicians to detect directly, such as low ejection fraction from a standard 12-lead ECG, future atrial fibrillation risk, early aortic stenosis from limited echocardiographic views, pulmonary hypertension signatures, or coronary plaque characteristics associated with future events. These applications can convert routine tests into higher-value screening tools without requiring entirely new hardware infrastructure.

AI-enabled cardiovascular imaging is becoming more quantitative and multimodal. Cardiac CT platforms are moving beyond stenosis assessment to plaque volume, plaque composition, vessel-specific disease burden, inflammation-related features, and ischemia estimation. Echocardiography platforms are automating acquisition guidance, chamber measurements, ejection fraction, strain, valve assessment, and disease classification. Cardiac MRI tools are accelerating segmentation, tissue characterization, and workflow. The strategic direction is toward a unified patient model that combines anatomy, function, physiology, and longitudinal risk rather than producing a single isolated measurement.

Signal intelligence is also improving. Ambulatory monitors and implantable devices are using AI to classify arrhythmias, suppress artifact, reduce false alerts, and rank transmissions according to clinical urgency. This is critical because remote device clinics often manage thousands of patients, and alert burden can overwhelm staff. The commercial value of an algorithm therefore depends on how much review time it removes and whether it improves sensitivity without creating excessive follow-up. Vendors with large proprietary ECG and device datasets have a structural advantage because performance can improve across diverse rhythms, devices, and care settings.

In procedural cardiology, manufacturers are combining AI with intravascular imaging, electroanatomic mapping, robotic navigation, and pre-procedure planning. AI-assisted optical coherence tomography can automate vessel measurements, characterize calcium, and support stent sizing. Structural heart platforms can automate annular sizing, assess access routes, simulate device placement, and improve case planning. Electrophysiology systems can use pattern recognition to organize complex signals and support lesion strategy. These technologies are raising the competitive bar because they influence the procedural workflow and can increase attachment of disposables, catheters, implants, and service contracts.

Edge AI and sensor fusion are expanding the device footprint outside hospitals. Smart stethoscopes, wearable ECG devices, handheld ultrasound, blood pressure systems, and home monitoring devices increasingly process data locally or transmit compact clinical outputs to cloud platforms. Edge processing can reduce latency, support intermittent connectivity, and limit transfer of raw data. Sensor fusion can combine acoustic, electrical, hemodynamic, motion, and contextual data to improve specificity. This is particularly relevant for heart failure and arrhythmia care, where no single physiologic signal reliably predicts deterioration in every patient.

Manufacturers are also differentiating through implementation architecture. The leading products integrate with existing ECG management systems, PACS, reporting tools, and EHR workflows rather than requiring separate portals. Single sign-on, structured reporting, automatic result routing, audit trails, and cybersecurity controls are becoming core product features. Health systems increasingly require local validation, silent-mode testing, performance dashboards, and escalation protocols before clinical activation. Companies that provide these capabilities can reduce deployment friction and move from departmental pilots to enterprise contracts.

The next innovation cycle will center on adaptive models, multimodal foundation models, digital twins, and closed-loop clinical support, but commercialization will remain constrained by regulation and liability. Most near-term devices will continue to operate as assistive systems with clinician oversight. The strongest products will not attempt to replace cardiologists; they will reduce uncertainty, standardize repetitive work, and surface information at the moment a decision must be made. This human-in-the-loop model is more compatible with U.S. clinical practice, reimbursement, and hospital risk management.

Segmentation Insights

The U.S. AI-Enabled Cardiovascular Devices Market is segmented on the basis of product category, application, end user, technology type, and region. The segmentation reflects how U.S. buyers’ budget for the technology, how the device is deployed inside clinical workflow, and where recurring revenue is generated.

By Product Category

AI-Enabled Cardiovascular Imaging and Visualization Systems
AI-enabled imaging and visualization systems represented the largest product category in 2025, accounting for an estimated one-third of market revenue. The segment includes AI modules embedded in echocardiography, cardiac CT, cardiac MRI, nuclear cardiology, angiography, and intravascular imaging platforms. Revenue is generated through scanner upgrades, workstation licenses, cloud analysis fees, enterprise contracts, and procedure-linked software. Demand is strongest where automation reduces sonographer dependence, shortens interpretation time, improves reproducibility, or generates quantitative measurements that influence intervention. Coronary CT plaque analysis, automated echo quantification, structural heart planning, and AI-assisted intravascular imaging are among the highest-value subsegments.

AI-ECG and Electrophysiology Analytics Devices
AI-ECG and electrophysiology analytics form one of the fastest-growing categories. This segment includes predictive algorithms applied to standard 12-lead ECGs, ambulatory rhythm analysis, arrhythmia classification, implantable monitor analytics, electroanatomic mapping intelligence, and device-clinic alert prioritization. Growth is supported by the low incremental cost of applying software to existing ECG infrastructure and the large volume of ECG testing performed in U.S. hospitals and clinics. Products that identify low ejection fraction, atrial fibrillation risk, pulmonary hypertension, hypertrophic cardiomyopathy, or clinically significant arrhythmias can expand the diagnostic value of a widely available test.

AI-Enabled Wearable and Ambulatory Cardiac Monitoring Devices
Wearable and ambulatory monitoring devices include patch ECG systems, mobile cardiac telemetry, connected Holter devices, smartwatches with regulated ECG functions, external loop recorders, smart stethoscopes, and multi-parameter home monitoring systems. AI is central to noise suppression, beat classification, event detection, symptom correlation, and triage. The category is attractive because it combines a physical device with recurring interpretation or monitoring revenue. Growth will be strongest in post-discharge surveillance, paroxysmal arrhythmia detection, heart failure monitoring, and decentralized clinical trials. Competitive differentiation depends on diagnostic yield, wear time, patient adherence, turnaround time, and the ability to integrate findings into cardiology workflow.

AI-Assisted Interventional and Procedural Cardiovascular Devices
AI-assisted interventional and procedural devices include intravascular imaging systems, coronary physiology platforms, structural heart planning tools, cath lab navigation, robotic or magnetic navigation, electrophysiology mapping, and software that supports device sizing or lesion strategy. These products are purchased on the basis of procedure quality and lab economics rather than broad population screening. Although the installed base is smaller than for ECG or imaging software, average revenue per account is higher because AI can influence capital equipment, disposables, catheters, stents, valves, and service contracts. Adoption is concentrated in high-volume academic and regional referral centers before expanding to community hospitals.

AI-Integrated Implantable and Therapeutic Cardiovascular Devices
AI-integrated implantable and therapeutic devices include pacemakers, implantable cardioverter defibrillators, cardiac resynchronization systems, insertable cardiac monitors, hemodynamic sensors, ventricular support systems, and other connected implants that use algorithms to detect events or prioritize clinical review. The AI-attributable revenue component is smaller than the full implant value, but it materially affects product differentiation and remote follow-up. Growth is supported by larger implanted-patient populations and the need to reduce device-clinic workload. Over time, algorithms are expected to become more personalized, combining device diagnostics with comorbidities, medication changes, and patient-reported data.

By Application

Coronary Artery Disease and Ischemia Assessment
Coronary artery disease is a major application segment because AI can improve both noninvasive and invasive decision-making. Cardiac CT algorithms quantify plaque, stenosis, vessel remodeling, calcium, and lesion-specific ischemia, while intravascular imaging systems support lesion preparation and stent optimization. The U.S. opportunity is being reinforced by expanded clinical acceptance of coronary CT angiography and improving reimbursement for advanced analysis. Providers value technologies that reduce unnecessary invasive angiography, identify high-risk plaque before an acute event, and standardize complex PCI planning.

Arrhythmia Detection and Rhythm Management
Arrhythmia detection is expected to record one of the highest CAGRs through 2035. Atrial fibrillation is frequently intermittent and underdiagnosed, while implanted and wearable devices generate large quantities of rhythm data. AI improves signal quality, classifies events, and enables risk-based worklists. The application spans consumer-accessible ECG, prescription ambulatory monitoring, implantable loop recorders, pacemakers, defibrillators, and electrophysiology systems. Revenue growth is driven by recurring monitoring, replacement cycles, and the expansion of ablation and rhythm-management programs.

Heart Failure Detection and Longitudinal Management
Heart failure is a strategically important application because deterioration often becomes visible only after congestion or symptoms have progressed. AI-enabled ECG, digital auscultation, echocardiography, hemodynamic monitoring, remote weight and blood pressure monitoring, and implantable device diagnostics can identify elevated risk earlier. U.S. hospitals are particularly interested in solutions that reduce readmissions, support transitions of care, and allow clinical teams to manage larger populations. The strongest business models combine device data with a clear intervention pathway rather than delivering a risk score without operational ownership.

Structural Heart and Valvular Disease
Structural heart applications include automated detection and grading of aortic, mitral, and tricuspid disease; echo and CT measurement; transcatheter valve planning; access assessment; and post-procedure surveillance. This is a premium market because device sizing and patient selection directly affect high-cost interventions. AI can reduce measurement variability and support multidisciplinary heart teams. As transcatheter therapies expand beyond aortic stenosis into mitral and tricuspid disease, manufacturers that integrate planning software with imaging systems and implant portfolios will gain strategic advantage.

Preventive Cardiology, Vascular Disease and Stroke Risk
Preventive applications include coronary calcium assessment, incidental cardiovascular findings, hypertension detection, vascular imaging, embolic risk, and population screening. AI enables opportunistic analysis of tests obtained for other reasons, turning existing imaging and ECG data into cardiovascular risk signals. The application is commercially important for primary care networks, payers, imaging centers, oncology programs, and employer health strategies. Adoption will depend on evidence that additional detection leads to appropriate treatment rather than unnecessary downstream testing.

By End User

Hospitals and Integrated Delivery Networks
Hospitals and integrated delivery networks are the dominant end users because they control major imaging platforms, cath labs, electrophysiology labs, implant programs, and acute cardiovascular care pathways. Large systems increasingly seek enterprise agreements that standardize AI across multiple sites. Their value analysis committees require cybersecurity review, data-use terms, interoperability, clinical evidence, budget impact, and defined accountability for alerts. Vendors that can demonstrate system-wide productivity and integrate with existing infrastructure are more likely to progress from pilot to scaled deployment.

Academic Medical Centers and Cardiac Specialty Centers
Academic medical centers and cardiac specialty centers are early adopters, validation partners, and reference sites. They have the specialist expertise and case complexity needed to evaluate advanced AI in structural heart, cardiac CT, MRI, electrophysiology, and heart failure. These institutions often influence guidelines, publish real-world evidence, and train clinicians from other centers. Their procurement cycles can be lengthy, but successful adoption creates high strategic value for manufacturers seeking national credibility.

Cardiology Practices and Diagnostic Imaging Centers
Cardiology practices and diagnostic imaging centers are increasingly important for AI-ECG, ambulatory monitoring, echocardiography, and coronary CT analysis. These users prioritize fast deployment, predictable reimbursement, low IT burden, and clear reporting. AI can improve throughput and allow smaller practices to offer advanced interpretation without maintaining every subspecialty on site. Cloud-based delivery and integration with existing reporting platforms are especially important in this segment.

Ambulatory Surgery Centers and Office-Based Laboratories
Ambulatory surgery centers and office-based laboratories represent an emerging end-user segment for selected vascular, electrophysiology, and diagnostic workflows. Complex structural heart and high-risk cardiac procedures remain hospital-centered, but outpatient migration creates demand for compact, efficient systems with lower capital intensity. AI-enabled procedure guidance, monitoring, and imaging can support standardization where staffing is leaner. Adoption will be influenced by payer policy, state regulation, and the ability to demonstrate safe patient selection.

Home Healthcare, Remote Monitoring and Virtual Cardiology Providers
Home healthcare, remote monitoring, and virtual cardiology providers are expected to post the fastest end-user growth. Their business models depend on connected devices, automated triage, and scalable clinician dashboards. Cardiovascular use cases include post-discharge heart failure surveillance, blood pressure management, arrhythmia detection, implanted-device follow-up, and medication-response monitoring. The market opportunity is significant, but providers must manage patient engagement, device logistics, false alerts, escalation protocols, and Medicare billing compliance.

By Technology Type

Machine Learning and Deep Learning
Machine learning and deep learning account for the largest technology share and underpin most imaging, ECG, and monitoring applications. Deep neural networks are particularly effective in image segmentation, waveform classification, and latent pattern recognition. Commercial performance depends on training data diversity, external validation, calibration, and control of model drift. Fixed algorithms remain dominant, while adaptive approaches will expand gradually as regulatory change-control frameworks mature.

Computer Vision and Automated Image Quantification
Computer vision is central to echocardiography, cardiac CT, MRI, angiography, and intravascular imaging. It automates contouring, chamber measurement, plaque characterization, vessel analysis, valve sizing, and image quality checks. The technology reduces inter-reader variability and supports standardized reporting. Growth is closely tied to the volume of advanced cardiovascular imaging and the ability to integrate outputs directly into existing workstations and procedure-planning systems.

AI Signal Processing and Digital Biomarkers
AI signal processing converts ECG, acoustic, pressure, impedance, pulse, and motion data into clinically interpretable biomarkers. It is the foundation of predictive ECG, smart stethoscopes, rhythm analytics, and implantable-device intelligence. This technology type can create new diagnostic capability from low-cost sensors, making it attractive for primary care and home use. Regulatory validation must address artifact, device variability, patient comorbidity, and performance across demographic subgroups.

Predictive Analytics and Clinical Decision Support
Predictive analytics combines device-generated data with clinical context to estimate deterioration, future arrhythmia, procedural risk, or treatment need. The highest-value systems connect prediction to a specific action, such as ordering confirmatory imaging, reviewing a high-risk transmission, adjusting heart failure therapy, or prioritizing an urgent study. Generic risk scores have limited commercial value unless they are embedded in a defined pathway and supported by prospective outcomes evidence.

Cloud-Connected, Edge AI and Sensor Fusion Platforms
Cloud-connected and edge AI platforms support distributed deployment across hospitals, clinics, and homes. Cloud delivery enables centralized updates, enterprise analytics, and large-scale monitoring, while edge processing reduces latency and connectivity dependence. Sensor fusion combines multiple physiologic signals to improve specificity. Hybrid architectures will dominate because U.S. providers require both scalable analytics and local resilience, with strong controls for privacy, cybersecurity, and device interoperability.

Regional Insights: Where the Market is Growing Fastest

The U.S. AI-Enabled Cardiovascular Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance is shaped by population size, cardiovascular disease burden, concentration of academic medical centers, access to advanced imaging, hospital system consolidation, medtech innovation clusters, payer mix, digital infrastructure, and availability of cardiovascular specialists. The South represented the largest regional market in 2025, while the West is projected to record the fastest growth through 2035. The Northeast remains the most evidence-intensive and high-acuity adoption region, and the Midwest provides a durable base of device manufacturing expertise, integrated systems, and mature cardiovascular programs.

South

The South accounted for an estimated USD 1.55 billion in 2025 and is projected to reach approximately USD 11.32 billion by 2035, expanding at an estimated CAGR of 22.0%. The region includes Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, the District of Columbia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas. Its leadership is supported by population growth, a high burden of hypertension, diabetes, obesity, heart failure, and vascular disease, and continued expansion of large hospital networks. The region also contains major cardiovascular referral centers and a rapidly growing base of outpatient and remote-care programs.

Texas is the largest Southern state market and one of the most important U.S. markets overall. With an estimated 2025 population of approximately 31.7 million, Texas combines scale with major medical hubs in Houston, Dallas–Fort Worth, Austin, and San Antonio. Large health systems and academic centers support adoption of AI-enabled cardiac CT, echocardiography, electrophysiology, structural heart planning, and remote monitoring. The state’s geographic size also strengthens the business case for remote interpretation and connected device follow-up. Florida, with approximately 23.5 million residents and a large older population, is a major demand center for arrhythmia detection, heart failure surveillance, valvular disease assessment, and ambulatory monitoring. AI-enabled devices that reduce specialist workload and support Medicare-heavy populations are particularly relevant.

Georgia, North Carolina, Virginia, Tennessee, and Maryland form a second tier of high-growth markets. Georgia’s population exceeded 11.3 million in 2025, and Atlanta-based health systems are expanding advanced imaging and digital care. North Carolina benefits from major academic centers, research networks, and fast population growth in the Research Triangle and Charlotte. Virginia and Maryland have sophisticated integrated systems, federal health connections, and dense specialist networks around Washington, D.C., Baltimore, Richmond, and Northern Virginia. Tennessee has strong cardiac specialty capacity in Nashville, Memphis, and Knoxville, while its rural areas create demand for remote monitoring and AI-assisted diagnostic access.

South Carolina, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, West Virginia, and Oklahoma have significant cardiovascular risk burden and uneven access to specialty care. In these states, market growth will come from two distinct channels. Large referral centers will adopt premium AI for cardiac imaging, electrophysiology, and procedural planning, while community hospitals and clinics will prioritize portable ultrasound, predictive ECG, digital auscultation, and remote patient monitoring. AI can help extend expertise, but successful deployment requires reliable connectivity, referral pathways, and reimbursement support. Delaware and the District of Columbia are smaller by population but have high provider density and access to major regional health systems.

The South’s procurement environment is increasingly concentrated. Large nonprofit and for-profit systems can standardize AI-enabled devices across multiple states, creating significant enterprise opportunities but demanding strong contracting flexibility and implementation capacity. Vendors must account for variation in payer mix, Medicaid exposure, rural hospital finances, and state telehealth rules. The region will remain the largest market because it combines high unmet clinical need with expanding infrastructure, but adoption will be heterogeneous. Solutions that demonstrate measurable reductions in readmission, interpretation time, or unnecessary referral will outperform products positioned only as advanced analytics.

West

The West generated an estimated USD 1.36 billion in 2025 and is forecast to reach approximately USD 11.05 billion by 2035, representing the fastest regional CAGR at about 23.3%. The region includes Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, Washington, Oregon, California, Alaska, and Hawaii. Growth is driven by a strong technology ecosystem, early adoption of digital health, large integrated delivery networks, venture funding, and a high concentration of AI, cloud, semiconductor, and medtech expertise. The West is especially influential in cardiac imaging, wearable monitoring, remote care, and software-led commercialization.

California is the dominant Western market and the largest U.S. state by population at approximately 39.4 million in 2025. The state combines major academic cardiovascular centers, large payer-provider systems, extensive imaging capacity, and a dense innovation cluster across the San Francisco Bay Area, Los Angeles, Orange County, and San Diego. California is a launch market for AI-enabled coronary CT, automated echo, virtual cardiology, remote monitoring, and digital biomarkers. Its health systems often conduct rigorous data governance and equity reviews, making the state both commercially attractive and operationally demanding. Companies that succeed in California gain valuable reference accounts and access to clinical partnerships.

Washington and Oregon have strong integrated delivery models and high digital readiness. Seattle-based technology expertise supports cloud-connected cardiovascular platforms, while major provider systems in Washington and Oregon are receptive to enterprise imaging and remote-care solutions that demonstrate workflow value. Arizona and Nevada are among the highest-growth state markets because of rapid population expansion and aging demographics. Phoenix, Tucson, Las Vegas, and Reno are increasing cardiovascular capacity, creating demand for AI-enabled rhythm monitoring, structural heart assessment, heart failure management, and imaging automation.

Colorado and Utah are important innovation and adoption markets. Colorado has sophisticated health systems in Denver and a growing base of digital health companies, while Utah combines integrated care, population health capability, and a strong technology workforce. Idaho and Montana are smaller but growing markets where remote interpretation, portable ultrasound, and connected monitoring can address distance and specialist scarcity. Wyoming, New Mexico, Alaska, and Hawaii have dispersed populations and access challenges that favor AI-enabled triage and virtual care, although procurement budgets and infrastructure constraints can slow adoption.

The West will gain share because AI-enabled cardiovascular care aligns with the region’s strengths in software, decentralized delivery, and technology partnerships. However, vendors must navigate strict privacy expectations, complex enterprise security review, and highly competitive talent markets. Reimbursement and evidence remain important, but Western health systems may adopt earlier when a solution supports strategic digital transformation or improves care access across a broad geography. The region is likely to lead in multimodal AI, cloud-based cardiac imaging, wearable-derived biomarkers, and integration of cardiovascular devices with virtual specialty care.

Northeast

The Northeast represented an estimated USD 1.12 billion in 2025 and is projected to reach approximately USD 7.41 billion by 2035, expanding at an estimated CAGR of 20.8%. The region includes Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania. It has the highest concentration of major academic medical centers, specialist physicians, clinical trial programs, and evidence-driven procurement committees. The Northeast is a critical region for validation and early adoption of AI-enabled cardiovascular devices, particularly in cardiac imaging, structural heart, electrophysiology, and complex heart failure care.

New York is the largest state market in the region, supported by approximately 20.0 million residents, high imaging and procedure volumes, and major systems in New York City, Long Island, Westchester, Albany, Rochester, and Buffalo. AI-enabled cardiovascular products can address substantial reading and monitoring workloads, but deployment often requires integration across complex multi-hospital environments. Massachusetts has a smaller population but disproportionate influence because of Boston’s academic hospitals, biomedical research institutions, and medtech ecosystem. The state is a key site for clinical validation, algorithm development, and early-stage company formation.

Pennsylvania and New Jersey are large, commercially important markets. Pennsylvania had approximately 13.1 million residents in 2025 and supports major cardiovascular programs in Philadelphia, Pittsburgh, Hershey, and regional health systems across the state. New Jersey benefits from proximity to New York and Philadelphia, a strong pharmaceutical and medtech presence, and dense ambulatory care. Connecticut and Rhode Island have smaller populations but high hospital and specialist density, supporting adoption of enterprise imaging and monitoring technologies.

Maine, New Hampshire, and Vermont have smaller state markets and more rural geographies. Their opportunity is concentrated in regional referral centers, remote interpretation, portable cardiac imaging, and monitoring platforms that extend specialist coverage. The Northeast’s overall growth rate is slightly below the West and South because the provider market is mature and population growth is slower. Nevertheless, average contract value can be high because hospitals purchase premium technologies, participate in clinical trials, and demand comprehensive implementation and evidence packages.

Procurement in the Northeast is highly analytical. Health systems frequently require peer-reviewed validation, subgroup performance, local data testing, and formal AI governance review. These requirements lengthen sales cycles but create durable contracts once a solution is embedded. Companies that can demonstrate prospective clinical utility, not merely retrospective accuracy, are best positioned. The region will remain central to adoption of AI for coronary plaque analysis, complex echo, cardiac MRI, structural heart planning, predictive ECG, and enterprise-level monitoring orchestration.

Midwest

The Midwest accounted for an estimated USD 0.82 billion in 2025 and is forecast to reach approximately USD 5.12 billion by 2035, reflecting an estimated CAGR of 20.1%. The region includes Ohio, Indiana, Illinois, Michigan, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota. Demand is supported by established cardiovascular programs, integrated delivery networks, a significant chronic disease burden, and a long-standing concentration of medical device manufacturing and cardiovascular expertise. The Midwest is a stable adoption market where clinical reliability, service support, and cost effectiveness are decisive.

Illinois, Ohio, Michigan, and Minnesota are the largest state opportunities. Illinois had approximately 12.7 million residents in 2025 and benefits from Chicago’s academic centers, community hospitals, and large cardiology networks. Ohio, with approximately 11.9 million residents, has nationally influential cardiovascular institutions and high procedure capacity across Cleveland, Columbus, Cincinnati, and regional systems. Michigan supports strong demand for heart failure, rhythm management, and imaging technologies. Minnesota is strategically important because of its medtech cluster, cardiovascular device heritage, major integrated systems, and experienced clinical engineering workforce.

Indiana, Wisconsin, and Missouri provide substantial community and regional referral demand. Indianapolis, Milwaukee, Madison, St. Louis, and Kansas City are important centers for advanced cardiac care, while surrounding areas create opportunities for remote monitoring and distributed diagnostic support. Iowa, Kansas, Nebraska, North Dakota, and South Dakota are smaller markets but well suited to AI-enabled devices that extend access across rural networks. Portable echo, predictive ECG, remote device surveillance, and cloud-based reading can reduce geographic barriers when linked to clear referral pathways.

The Midwest’s purchasing culture often emphasizes operational dependability and measurable return on investment. Hospitals may be less willing to pay for unproven premium features, but they can scale technology quickly when it reduces staffing burden or standardizes care across a network. Manufacturer service capability and clinical education are especially important. The region will remain a strong market for AI-enabled implantable monitoring, electrophysiology analytics, echocardiography automation, heart failure surveillance, and enterprise cardiovascular workflow tools.

Key Market Players

The U.S. AI-Enabled Cardiovascular Devices Competitive Landscape includes diversified imaging and medtech companies, cardiac monitoring specialists, and software-focused innovators. The market is fragmented by workflow but increasingly consolidated through partnerships and acquisitions. Large manufacturers benefit from installed equipment, service organizations, and enterprise contracting. Specialized companies can compete by delivering superior algorithms, proprietary datasets, faster workflow, or differentiated reimbursement. Competitive advantage is determined by FDA authorization, evidence quality, interoperability, data access, reimbursement, cybersecurity, and the ability to scale implementation.

Platform competition is intensifying. Imaging manufacturers are embedding AI across scanner and workstation portfolios. Cardiac monitoring companies are using large proprietary signal datasets to improve classification and triage. Cardiovascular software companies are expanding from single measurements to disease-management platforms. Device manufacturers are integrating AI with intravascular imaging, implantable monitors, pacemakers, defibrillators, mapping systems, and procedure planning. Partnerships between algorithm developers and established manufacturers will remain common because they combine innovation speed with distribution and regulatory infrastructure.

Some of the key players in the U.S. AI-Enabled Cardiovascular Devices industry are

1. GE HealthCare
2. Siemens Healthineers
3. Philips
4. Abbott Laboratories
5. Medtronic
6. Boston Scientific Corporation
7. Johnson & Johnson MedTech
8. Edwards Lifesciences
9. iRhythm Technologies
10. HeartFlow
11. Cleerly
12. Viz.ai
13. Eko Health
14. AliveCor
15. Tempus AI
16. Anumana
17. Ultromics
18. Us2.ai
19. Elucid
20. CathWorks
21. Circle Cardiovascular Imaging
22. Artrya
23. iCardio.ai
24. MyCardium AI
25. Murj

GE HealthCare, Siemens Healthineers, and Philips have strong positions in imaging, ultrasound, monitoring, and enterprise workflow. Abbott, Medtronic, Boston Scientific, Johnson & Johnson MedTech, and Edwards Lifesciences can integrate AI with high-value interventional, rhythm, implantable, and structural heart portfolios. iRhythm, HeartFlow, Cleerly, Viz.ai, Eko Health, AliveCor, Tempus AI, Anumana, Ultromics, Us2.ai, Elucid, CathWorks, Circle Cardiovascular Imaging, Artrya, iCardio.ai, MyCardium AI, and Murj compete through specialized datasets, focused regulatory claims, cloud delivery, and workflow differentiation. Market share through 2035 will be influenced by clinical utility, payer coverage, hospital contracting, algorithm transparency, and the ability to prove performance after deployment.

Recent Developments

Recent developments show that the U.S. market is moving from pilot-stage AI toward reimbursed and workflow-integrated cardiovascular devices. In 2025, the FDA issued comprehensive draft guidance covering lifecycle management and marketing submissions for AI-enabled device software functions. The framework emphasizes data management, performance evaluation, transparency, bias control, cybersecurity, and post-market monitoring. This development is important because it raises the standard for commercial durability and gives health systems a clearer basis for vendor evaluation.

Predictive ECG expanded materially during 2024–2026. FDA-cleared algorithms entered the market for future atrial fibrillation risk, low left ventricular ejection fraction, and pulmonary hypertension-related signals. These products demonstrate a shift from interpreting visible ECG abnormalities to detecting latent disease signatures. The commercial opportunity is significant because standard 12-lead ECG infrastructure is already widespread. Separate hospital outpatient payment for certain assistive algorithmic ECG assessments beginning in 2025 improved the reimbursement pathway and reduced a major barrier to clinical adoption.

AI-enabled coronary and intravascular imaging also advanced. New clearances and software upgrades improved automated plaque analysis, coronary measurement, calcium characterization, and stent planning. In 2026, next-generation AI-powered coronary imaging software received U.S. clearance to combine high-resolution intravascular images with automated procedural insights. Payer coverage expanded for selected AI-assisted coronary CT analysis, supporting broader use in the assessment of coronary artery disease. These developments increase the likelihood that AI will become a standard component of advanced coronary imaging rather than an optional add-on.

Echocardiography and point-of-care cardiac assessment continued to broaden. AI-enabled digital stethoscopes gained clearance for rapid low-ejection-fraction detection, and AI platforms expanded automated measurements and disease classification from limited ultrasound views. This creates a pathway to move cardiovascular screening into primary care, emergency medicine, and community settings. However, manufacturers must show that positive findings lead to timely confirmatory testing and appropriate treatment to avoid unnecessary utilization.

The market is also seeing increased integration between AI companies and large medtech or imaging vendors. Acquisitions, licensing, and OEM partnerships allow algorithms to reach installed hardware bases, while established manufacturers gain software differentiation and recurring revenue. Investment remains strongest in companies with FDA-authorized products, clear reimbursement, proprietary longitudinal datasets, and evidence that connects algorithm output to improved clinical or economic outcomes.

Conclusion

The U.S. AI-Enabled Cardiovascular Devices Market Size & Share is positioned for rapid expansion from USD 4.85 billion in 2025 to approximately USD 34.85 billion by 2035, supported by a CAGR of 21.80% during the forecast period. Historical growth from USD 2.28 billion in 2021 reflects the rapid increase in FDA-authorized AI devices, greater availability of cardiovascular data, expanding reimbursement, and urgent demand for clinical workflow automation. The market’s long-term strength is grounded in the scale of cardiovascular disease, specialist capacity constraints, and the economic value of earlier diagnosis and better procedural decisions.

The most attractive growth opportunities will be in AI-enabled cardiac imaging, predictive ECG, ambulatory rhythm monitoring, heart failure surveillance, coronary plaque analysis, structural heart planning, intravascular imaging, and implantable-device analytics. Imaging will remain the largest revenue category, while predictive ECG and remote monitoring are expected to grow faster because they can scale across existing infrastructure and generate recurring revenue. Interventional and implantable applications will create high-value platform opportunities where AI increases utilization of associated devices and consumables.

Regional opportunity will be led by the South due to population scale and disease burden, followed closely by the West because of technology adoption and innovation density. The Northeast will remain essential for evidence generation and premium clinical adoption, while the Midwest will provide stable demand and strong medtech infrastructure. At the state level, California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Massachusetts, Minnesota, Washington, Arizona, and Michigan will be especially important for manufacturers and investors.

For clients evaluating this market, the central question is not whether AI will enter cardiovascular devices; it is where AI will become indispensable to clinical workflow and how value will be captured. Products that only add a score or image overlay will face increasing commoditization. Products that reduce labor, improve diagnostic consistency, guide high-cost intervention, create reimbursable services, or support longitudinal care will command stronger adoption. Companies that combine validated algorithms, device integration, reimbursement strategy, enterprise implementation, and real-world performance monitoring will define the competitive structure of the U.S. AI-enabled cardiovascular devices industry through 2035.

TABLE OF CONTENT

1. U.S. AI-Enabled Cardiovascular Devices Market: Market Introduction & Context
1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry and Clinical Collaborations
1.3.4. In-House Research Databases
1.3.5. AI Medical Device Classification and Revenue Attribution Framework
1.3.6. Analytical Frameworks & Forecasting Models
1.3.7. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.5. AI-Enabled Cardiovascular Device Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Cardiovascular Device and Imaging System Manufacturers
1.6.2. AI Algorithm, Clinical Software and Digital Biomarker Developers
1.6.3. Semiconductor, Sensor, Cloud, Cybersecurity and Component Suppliers
1.6.4. Hospitals, Integrated Delivery Networks and Cardiac Service Lines
1.6.5. Cardiology Practices, Imaging Centers and Specialty Heart Centers
1.6.6. Remote Monitoring, Virtual Cardiology and Home Healthcare Providers
1.6.7. Group Purchasing Organizations, Distributors and Technology Integrators
1.6.8. Payers, FDA, CMS and Clinical Decision-Makers
What this section provides: This section defines the market boundary, study scope, research methodology, revenue-attribution rules, assumptions, and stakeholder ecosystem used to measure the U.S. AI-enabled cardiovascular devices market.

2. U.S. AI-Enabled Cardiovascular Devices Market: Executive Summary
2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. High-Growth Product and Clinical Opportunity Areas
2.8. Leading Regional and State-Level Adoption Hotspots
What this section provides: This section gives decision-makers a concise view of market size, growth direction, leading AI-enabled product categories, clinical use cases, competitive intensity, and priority commercial opportunities.

3. U.S. AI-Enabled Cardiovascular Devices Market: Market Dynamics & Outlook
3.1. Drivers and Their Impact Analysis
3.1.1. Rising U.S. Cardiovascular Disease and Diagnostic Burden
3.1.2. Increasing Volumes of Cardiovascular Imaging, ECG and Physiologic Data
3.1.3. Cardiologist, Sonographer and Device-Clinic Workforce Constraints
3.1.4. Expansion of Remote Cardiac Monitoring and Connected Care
3.1.5. Demand for Faster, More Reproducible and Quantitative Cardiovascular Workflows
3.1.6. Growth of Minimally Invasive Structural Heart and Electrophysiology Procedures
3.2. Restraints and Their Impact Analysis
3.2.1. High Clinical Validation and Regulatory Evidence Requirements
3.2.2. Interoperability Barriers Across Imaging, EHR and Device Platforms
3.2.3. Cybersecurity, Privacy and Data Governance Risk
3.2.4. Uncertain Reimbursement and Hospital Return-on-Investment Thresholds
3.2.5. Algorithm Bias, Generalizability and Clinician-Trust Concerns
3.3. Opportunities and Their Impact Analysis
3.3.1. AI-Enabled Coronary CT, Plaque and Ischemia Assessment
3.3.2. Predictive ECG and Arrhythmia Detection
3.3.3. Automated Echocardiography and Structural Heart Planning
3.3.4. AI-Based Heart Failure Risk Stratification and Readmission Reduction
3.3.5. Implantable Device-Clinic Triage and Alert Prioritization
3.3.6. Edge AI, Sensor Fusion and Decentralized Cardiovascular Monitoring
3.4. Challenges and Their Impact Analysis
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Hospital Capital Procurement and Enterprise AI Buying Behavior Analysis
3.8. Algorithm Validation, Model Drift and Post-Market Performance Analysis
What this section provides: This section explains the clinical, commercial, operational, regulatory, reimbursement, and technical forces shaping demand and helps clients evaluate both market upside and implementation risk.

4. U.S. AI-Enabled Cardiovascular Devices Market: Market Environment & Industry Analysis
4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers and Data Partners
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization, Cloud Connectivity and Virtual Cardiology
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework for AI-Enabled Medical Devices
4.7.1. 510(k), De Novo and Premarket Approval Pathways
4.7.2. Predetermined Change Control Plans and Lifecycle Management
4.7.3. Good Machine Learning Practice and Real-World Performance Monitoring
4.8. CMS Reimbursement, Coding and Coverage Landscape
4.9. HIPAA, Data Privacy and Cybersecurity Requirements
4.10. EHR, PACS, DICOM and Cardiovascular Information System Interoperability
4.11. Import/Export Restrictions, Semiconductor Availability and Tariff Impact
4.12. Government Initiatives, Public Health Programs and AI Policy Direction
4.13. Impact of Escalating Geopolitical Tensions
4.14. Hospital Value Analysis Committee and Enterprise AI Governance Framework
What this section provides: This section provides a complete view of the external market environment, including regulation, reimbursement, pricing, cybersecurity, interoperability, supply chain, AI governance, and hospital procurement requirements.

5. U.S. AI-Enabled Cardiovascular Devices Market – By Product Category
5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. AI-Enabled Cardiovascular Imaging and Visualization Systems
5.1.2.1. AI-Enabled Echocardiography Systems
5.1.2.2. AI-Enabled Cardiac CT and Coronary Analysis Platforms
5.1.2.3. AI-Enabled Cardiac MRI and Nuclear Cardiology Systems
5.1.2.4. AI-Enabled Angiography and Intravascular Imaging Systems
5.1.3. AI-ECG and Electrophysiology Analytics Devices
5.1.3.1. Predictive 12-Lead ECG Systems
5.1.3.2. Ambulatory Rhythm Analytics Platforms
5.1.3.3. Electrophysiology Mapping and Ablation Intelligence Systems
5.1.3.4. Implantable Device Alert and Rhythm-Triage Analytics
5.1.4. AI-Enabled Wearable and Ambulatory Cardiac Monitoring Devices
5.1.4.1. Patch-Based ECG and Mobile Cardiac Telemetry Devices
5.1.4.2. Connected Holter and External Loop Recorders
5.1.4.3. Smartwatches and Regulated Consumer-Connected ECG Devices
5.1.4.4. Smart Stethoscopes and Multi-Parameter Home Monitoring Devices
5.1.5. AI-Assisted Interventional and Procedural Cardiovascular Devices
5.1.5.1. AI-Assisted Coronary Physiology and PCI Guidance Systems
5.1.5.2. Structural Heart Planning, Sizing and Navigation Systems
5.1.5.3. Cath Lab and Robotic Navigation Platforms
5.1.5.4. AI-Assisted Vascular and Endovascular Procedure Systems
5.1.6. AI-Integrated Implantable and Therapeutic Cardiovascular Devices
5.1.6.1. Pacemakers, ICDs and Cardiac Resynchronization Devices
5.1.6.2. Insertable Cardiac Monitors and Implantable Rhythm Sensors
5.1.6.3. Implantable Hemodynamic and Heart Failure Monitoring Devices
5.1.6.4. Connected Mechanical Circulatory Support and Therapeutic Systems
What this section provides: This section identifies the AI-enabled cardiovascular device categories expected to generate the largest revenue contribution, strongest recurring revenue, and highest growth through 2035.

6. U.S. AI-Enabled Cardiovascular Devices Market – By Application
6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Coronary Artery Disease and Ischemia Assessment
6.1.2.1. Coronary Plaque and Stenosis Quantification
6.1.2.2. Noninvasive Ischemia and Fractional Flow Assessment
6.1.2.3. Intravascular Imaging and PCI Optimization
6.1.3. Arrhythmia Detection and Rhythm Management
6.1.3.1. Atrial Fibrillation Detection
6.1.3.2. Bradyarrhythmia and Ventricular Arrhythmia Detection
6.1.3.3. Electrophysiology Procedure Planning and Mapping
6.1.3.4. Implantable Device Follow-Up and Alert Prioritization
6.1.4. Heart Failure Detection and Longitudinal Management
6.1.4.1. Early Heart Failure Detection and Risk Prediction
6.1.4.2. Congestion and Hemodynamic Monitoring
6.1.4.3. Readmission Prevention and Post-Discharge Surveillance
6.1.5. Structural Heart and Valvular Disease
6.1.5.1. Valve Disease Detection and Quantification
6.1.5.2. Transcatheter Valve Planning and Device Sizing
6.1.5.3. Post-Procedure Surveillance and Outcome Assessment
6.1.6. Preventive Cardiology, Vascular Disease and Stroke Risk
6.1.6.1. Cardiovascular Risk Screening and Incidental Findings
6.1.6.2. Hypertension and Vascular Risk Management
6.1.6.3. Peripheral Vascular Disease Assessment
6.1.6.4. Embolic and Stroke-Risk Identification
What this section provides: This section helps clients prioritize clinical applications according to patient burden, diagnostic and procedural volumes, reimbursement relevance, workflow value, and AI-enabled device innovation.

7. U.S. AI-Enabled Cardiovascular Devices Market – By End User
7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Integrated Delivery Networks
7.1.3. Academic Medical Centers and Cardiac Specialty Centers
7.1.4. Cardiology Practices and Diagnostic Imaging Centers
7.1.5. Ambulatory Surgery Centers and Office-Based Laboratories
7.1.6. Home Healthcare, Remote Monitoring and Virtual Cardiology Providers
What this section provides: This section explains which U.S. care settings and customer groups will drive enterprise purchasing, device utilization, software licensing, recurring monitoring revenue, and scaled AI deployment.

8. U.S. AI-Enabled Cardiovascular Devices Market – By Technology Type
8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Machine Learning and Deep Learning
8.1.3. Computer Vision and Automated Image Quantification
8.1.4. AI Signal Processing and Digital Biomarkers
8.1.5. Predictive Analytics and Clinical Decision Support
8.1.6. Cloud-Connected, Edge AI and Sensor Fusion Platforms
What this section provides: This section evaluates the core AI technologies shaping cardiovascular diagnosis, intervention, implantable-device intelligence, remote monitoring, and clinical decision support.

9. U.S. AI-Enabled Cardiovascular Devices Market – By Procurement Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Health System Enterprise Procurement
9.1.3. OEM-Embedded and Capital Equipment Platform Procurement
9.1.4. Cloud Subscription, Software-as-a-Medical-Device and Per-Analysis Licensing
9.1.5. Group Purchasing Organization, Distributor and Technology Integrator Channels
9.1.6. Payer-Provider, Remote Monitoring and Population Health Program Contracts
What this section provides: This section explains how AI-enabled cardiovascular devices are purchased and commercialized through enterprise agreements, OEM platforms, subscription licensing, channel partners, and value-based monitoring programs.

10. U.S. AI-Enabled Cardiovascular Devices Market – By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Cardiovascular Disease Burden, Procedure Volume and Hospital Infrastructure Analysis
10.1.4. Regional AI Adoption, Reimbursement and Procurement Dynamics
10.1.5. Regional Digital Infrastructure, Specialist Density and Innovation Ecosystem Analysis
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region AI-Enabled Cardiovascular Device Key Manufacturers, Health Systems and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region AI-Enabled Cardiovascular Device Key Manufacturers, Health Systems and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region AI-Enabled Cardiovascular Device Key Manufacturers, Health Systems and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region AI-Enabled Cardiovascular Device Key Manufacturers, Health Systems and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)
What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, helping clients identify AI adoption hotspots, cardiovascular procedure hubs, leading health systems, digital-infrastructure advantages, procurement patterns, and state-level commercial opportunities.

11. U.S. AI-Enabled Cardiovascular Devices Market: Competitive Landscape & Company Profiles
11.1. Market Share Analysis, 2025
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Company Profiles
11.3.1. GE HealthCare
11.3.2. Siemens Healthineers
11.3.3. Philips
11.3.4. Abbott Laboratories
11.3.5. Medtronic
11.3.6. Boston Scientific Corporation
11.3.7. Johnson & Johnson MedTech
11.3.8. Edwards Lifesciences
11.3.9. iRhythm Technologies
11.3.10. HeartFlow
11.3.11. Cleerly
11.3.12. Viz.ai
11.3.13. Eko Health
11.3.14. AliveCor
11.3.15. Tempus AI
11.3.16. Anumana
11.3.17. Ultromics
11.3.18. Us2.ai
11.3.19. Elucid
11.3.20. CathWorks
11.3.21. Circle Cardiovascular Imaging
11.3.22. Artrya
11.3.23. iCardio.ai
11.3.24. MyCardium AI
11.3.25. Murj
Note: Each company profile will include company overview, AI-enabled cardiovascular device and software portfolio, U.S. market strategy, regulatory status, clinical evidence, financial or funding positioning, partnerships, cybersecurity and interoperability capabilities, and recent developments.
What this section provides: This section provides competitor benchmarking, market-share visibility, portfolio positioning, regulatory and evidence comparison, partnership intelligence, and strategic analysis of leading AI-enabled cardiovascular device companies.

12. U.S. AI-Enabled Cardiovascular Devices Market: Future Market Outlook, 2026–2035
12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Multimodal Cardiovascular AI and Foundation Models
12.2.2. Predictive ECG and Low-Cost Population Screening
12.2.3. Autonomous Echocardiography and Automated Image Acquisition
12.2.4. AI-Enabled Coronary Plaque Analysis and Patient-Specific Procedure Planning
12.2.5. Closed-Loop Implantable Device Intelligence and Remote Monitoring
12.2.6. Edge AI, Digital Biomarkers and Multi-Sensor Fusion
12.3. Emerging Business and Commercialization Trends
12.4. Business Opportunities for Startups and Existing Players
12.5. Investment Prioritization Matrix
12.6. Market Consolidation, Partnership and Acquisition Outlook
What this section provides: This section prepares clients for future technology shifts, adoption scenarios, business-model changes, consolidation, investment priorities, and emerging opportunities through 2035.

13. U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations
13.1. Recommendations for Cardiovascular Device and Imaging Manufacturers
13.2. Recommendations for Hospitals, Health Systems and Cardiac Service Lines
13.3. Recommendations for Investors, Private Equity and Venture Capital Firms
13.4. Recommendations for AI Algorithm and Clinical Software Developers
13.5. Recommendations for Distributors, Cloud Providers and Technology Integrators
13.6. Recommendations for New Entrants and Startups
13.7. U.S. Go-to-Market and Reimbursement Strategy Considerations
13.8. Product Positioning, Evidence Generation and Portfolio Expansion Guidance
What this section provides: This section converts market intelligence into actionable recommendations for product development, evidence generation, regulatory planning, commercialization, enterprise selling, investment, partnerships, and competitive differentiation.

14. U.S. AI-Enabled Cardiovascular Devices Market: Disclaimer
14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Forecasting Limitation
14.4. AI Technology and Regulatory Change Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
What this section provides: This section clarifies the report’s scope, data-use terms, forecasting assumptions, technology and regulatory limitations, and legal boundaries.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. AI-Enabled Cardiovascular Devices Market: Market Definition and Scope
TABLE 3: U.S. AI-Enabled Cardiovascular Devices Market: Research Methodology Framework
TABLE 4: U.S. AI-Enabled Cardiovascular Devices Market: AI Medical Device Classification and Revenue Attribution Framework
TABLE 5: U.S. AI-Enabled Cardiovascular Devices Market: Key Assumptions
TABLE 6: U.S. AI-Enabled Cardiovascular Devices Market: AI-Enabled Cardiovascular Device Ecosystem Overview
TABLE 7: U.S. AI-Enabled Cardiovascular Devices Market: Stakeholder Analysis
TABLE 8: U.S. AI-Enabled Cardiovascular Devices Market: Executive Summary Snapshot, 2025
TABLE 9: U.S. AI-Enabled Cardiovascular Devices Market: Analyst Viewpoint Summary
TABLE 10: U.S. AI-Enabled Cardiovascular Devices Market: Market Attractiveness Index
TABLE 11: U.S. AI-Enabled Cardiovascular Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 12: U.S. AI-Enabled Cardiovascular Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. AI-Enabled Cardiovascular Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. AI-Enabled Cardiovascular Devices Market: High-Growth Product and Clinical Opportunity Areas
TABLE 15: U.S. AI-Enabled Cardiovascular Devices Market: Leading Regional and State-Level Adoption Hotspots
TABLE 16: U.S. AI-Enabled Cardiovascular Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. AI-Enabled Cardiovascular Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. AI-Enabled Cardiovascular Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. AI-Enabled Cardiovascular Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. AI-Enabled Cardiovascular Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. AI-Enabled Cardiovascular Devices Market: Clinical Workflow Economics Matrix
TABLE 22: U.S. AI-Enabled Cardiovascular Devices Market: Hospital Capital Procurement and Enterprise AI Buying Behavior Matrix
TABLE 23: U.S. AI-Enabled Cardiovascular Devices Market: Algorithm Validation, Model Drift and Post-Market Performance Matrix
TABLE 24: U.S. AI-Enabled Cardiovascular Devices Market: PESTEL Analysis
TABLE 25: U.S. AI-Enabled Cardiovascular Devices Market: Porter’s Five Forces Analysis
TABLE 26: U.S. AI-Enabled Cardiovascular Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 27: U.S. AI-Enabled Cardiovascular Devices Market: Value Chain Analysis
TABLE 28: U.S. AI-Enabled Cardiovascular Devices Market: Supply Chain Analysis
TABLE 29: U.S. AI-Enabled Cardiovascular Devices Market: Digitalization, Cloud Connectivity and Virtual Cardiology Impact
TABLE 30: U.S. AI-Enabled Cardiovascular Devices Market: Application & Innovation Landscape
TABLE 31: U.S. AI-Enabled Cardiovascular Devices Market: FDA Regulatory Framework for AI-Enabled Medical Devices
TABLE 32: U.S. AI-Enabled Cardiovascular Devices Market: Predetermined Change Control Plans and AI Lifecycle Management
TABLE 33: U.S. AI-Enabled Cardiovascular Devices Market: CMS Reimbursement, Coding and Coverage Landscape
TABLE 34: U.S. AI-Enabled Cardiovascular Devices Market: HIPAA, Data Privacy and Cybersecurity Requirements
TABLE 35: U.S. AI-Enabled Cardiovascular Devices Market: EHR, PACS, DICOM and Cardiovascular Information System Interoperability
TABLE 36: U.S. AI-Enabled Cardiovascular Devices Market: Semiconductor Availability, Import/Export Restrictions and Tariff Impact
TABLE 37: U.S. AI-Enabled Cardiovascular Devices Market: Government Initiatives, Public Health Programs and AI Policy Direction
TABLE 38: U.S. AI-Enabled Cardiovascular Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 39: U.S. AI-Enabled Cardiovascular Devices Market: Hospital Value Analysis Committee and Enterprise AI Governance Framework
TABLE 40: U.S. AI-Enabled Cardiovascular Devices Market: Product Category Snapshot, 2025
TABLE 41: Segment Dashboard; Definition and Scope, by Product Category
TABLE 42: U.S. AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 43: U.S. AI-Enabled Cardiovascular Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 44: U.S. AI-Enabled Cardiovascular Devices Market: AI-Enabled Cardiovascular Imaging and Visualization Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. AI-Enabled Cardiovascular Devices Market: AI-ECG and Electrophysiology Analytics Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. AI-Enabled Cardiovascular Devices Market: AI-Enabled Wearable and Ambulatory Cardiac Monitoring Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 47: U.S. AI-Enabled Cardiovascular Devices Market: AI-Assisted Interventional and Procedural Cardiovascular Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: U.S. AI-Enabled Cardiovascular Devices Market: AI-Integrated Implantable and Therapeutic Cardiovascular Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. AI-Enabled Cardiovascular Devices Market: Application Snapshot, 2025
TABLE 50: Segment Dashboard; Definition and Scope, by Application
TABLE 51: U.S. AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 52: U.S. AI-Enabled Cardiovascular Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 53: U.S. AI-Enabled Cardiovascular Devices Market: Coronary Artery Disease and Ischemia Assessment Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. AI-Enabled Cardiovascular Devices Market: Arrhythmia Detection and Rhythm Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. AI-Enabled Cardiovascular Devices Market: Heart Failure Detection and Longitudinal Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 56: U.S. AI-Enabled Cardiovascular Devices Market: Structural Heart and Valvular Disease Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 57: U.S. AI-Enabled Cardiovascular Devices Market: Preventive Cardiology, Vascular Disease and Stroke Risk Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. AI-Enabled Cardiovascular Devices Market: End User Snapshot, 2025
TABLE 59: Segment Dashboard; Definition and Scope, by End User
TABLE 60: U.S. AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 61: U.S. AI-Enabled Cardiovascular Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 62: U.S. AI-Enabled Cardiovascular Devices Market: Hospitals and Integrated Delivery Networks Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. AI-Enabled Cardiovascular Devices Market: Academic Medical Centers and Cardiac Specialty Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. AI-Enabled Cardiovascular Devices Market: Cardiology Practices and Diagnostic Imaging Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 65: U.S. AI-Enabled Cardiovascular Devices Market: Ambulatory Surgery Centers and Office-Based Laboratories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 66: U.S. AI-Enabled Cardiovascular Devices Market: Home Healthcare, Remote Monitoring and Virtual Cardiology Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. AI-Enabled Cardiovascular Devices Market: Technology Type Snapshot, 2025
TABLE 68: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 69: U.S. AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 70: U.S. AI-Enabled Cardiovascular Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 71: U.S. AI-Enabled Cardiovascular Devices Market: Machine Learning and Deep Learning Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. AI-Enabled Cardiovascular Devices Market: Computer Vision and Automated Image Quantification Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. AI-Enabled Cardiovascular Devices Market: AI Signal Processing and Digital Biomarkers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 74: U.S. AI-Enabled Cardiovascular Devices Market: Predictive Analytics and Clinical Decision Support Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 75: U.S. AI-Enabled Cardiovascular Devices Market: Cloud-Connected, Edge AI and Sensor Fusion Platforms Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. AI-Enabled Cardiovascular Devices Market: Procurement Channel Snapshot, 2025
TABLE 77: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 78: U.S. AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 79: U.S. AI-Enabled Cardiovascular Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 80: U.S. AI-Enabled Cardiovascular Devices Market: Direct Hospital and Health System Enterprise Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. AI-Enabled Cardiovascular Devices Market: OEM-Embedded and Capital Equipment Platform Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 82: U.S. AI-Enabled Cardiovascular Devices Market: Cloud Subscription, Software-as-a-Medical-Device and Per-Analysis Licensing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 83: U.S. AI-Enabled Cardiovascular Devices Market: Group Purchasing Organization, Distributor and Technology Integrator Channels Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 84: U.S. AI-Enabled Cardiovascular Devices Market: Payer-Provider, Remote Monitoring and Population Health Program Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 85: U.S. AI-Enabled Cardiovascular Devices Market: Regional Snapshot, 2025
TABLE 86: Segment Dashboard; Definition and Scope, by Region
TABLE 87: U.S. AI-Enabled Cardiovascular Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 88: U.S. AI-Enabled Cardiovascular Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 89: West Region U.S. AI-Enabled Cardiovascular Devices Market: Regional Overview and Trends
TABLE 90: West Region U.S. AI-Enabled Cardiovascular Devices Market: Key Manufacturers, AI Developers and Procurement Ecosystem
TABLE 91: West Region U.S. AI-Enabled Cardiovascular Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 95: West Region U.S. AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 96: West Region U.S. AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 97: California AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 98: California AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 99: California AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 100: California AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 101: California AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 102: Washington AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 103: Washington AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 104: Washington AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 105: Washington AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 106: Washington AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 107: Arizona AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 108: Arizona AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 109: Arizona AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 110: Arizona AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 111: Arizona AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 112: Colorado AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 113: Colorado AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 114: Colorado AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 115: Colorado AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 116: Colorado AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 117: Oregon AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 118: Oregon AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 119: Oregon AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 120: Oregon AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 121: Oregon AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 122: Utah AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 123: Utah AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 124: Utah AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 125: Utah AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 126: Utah AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 127: Nevada AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 128: Nevada AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 129: Nevada AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 130: Nevada AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 131: Nevada AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 132: New Mexico AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 133: New Mexico AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 134: New Mexico AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 135: New Mexico AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 136: New Mexico AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 137: Idaho AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 138: Idaho AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 139: Idaho AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 140: Idaho AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 141: Idaho AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 142: Montana AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 143: Montana AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 144: Montana AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 145: Montana AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 146: Montana AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 147: Wyoming AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 148: Wyoming AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 149: Wyoming AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 150: Wyoming AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 151: Wyoming AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 152: Alaska AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 153: Alaska AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 154: Alaska AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 155: Alaska AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 156: Alaska AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 157: Hawaii AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 158: Hawaii AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 159: Hawaii AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 160: Hawaii AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 161: Hawaii AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 162: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market: Regional Overview and Trends
TABLE 163: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market: Key Manufacturers, AI Developers and Procurement Ecosystem
TABLE 164: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 165: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 166: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 167: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 168: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 169: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 170: New York AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 171: New York AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 172: New York AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 173: New York AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 174: New York AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 175: Massachusetts AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 176: Massachusetts AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 177: Massachusetts AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 178: Massachusetts AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 179: Massachusetts AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 180: New Jersey AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 181: New Jersey AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 182: New Jersey AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 183: New Jersey AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 184: New Jersey AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 185: Pennsylvania AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 186: Pennsylvania AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 187: Pennsylvania AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 188: Pennsylvania AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 189: Pennsylvania AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 190: Connecticut AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 191: Connecticut AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 192: Connecticut AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 193: Connecticut AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 194: Connecticut AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 195: Maine AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 196: Maine AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 197: Maine AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 198: Maine AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 199: Maine AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 200: Vermont AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 201: Vermont AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 202: Vermont AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 203: Vermont AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 204: Vermont AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 205: New Hampshire AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 206: New Hampshire AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 207: New Hampshire AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 208: New Hampshire AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 209: New Hampshire AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 210: Rhode Island AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 211: Rhode Island AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 212: Rhode Island AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 213: Rhode Island AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 214: Rhode Island AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 215: Delaware AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 216: Delaware AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 217: Delaware AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 218: Delaware AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 219: Delaware AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 220: South Region U.S. AI-Enabled Cardiovascular Devices Market: Regional Overview and Trends
TABLE 221: South Region U.S. AI-Enabled Cardiovascular Devices Market: Key Manufacturers, AI Developers and Procurement Ecosystem
TABLE 222: South Region U.S. AI-Enabled Cardiovascular Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 223: South Region U.S. AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 224: South Region U.S. AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 225: South Region U.S. AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 226: South Region U.S. AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 227: South Region U.S. AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 228: Texas AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 229: Texas AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 230: Texas AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 231: Texas AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 232: Texas AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 233: Florida AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 234: Florida AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 235: Florida AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 236: Florida AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 237: Florida AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 238: Georgia AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 239: Georgia AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 240: Georgia AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 241: Georgia AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 242: Georgia AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 243: North Carolina AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 244: North Carolina AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 245: North Carolina AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 246: North Carolina AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 247: North Carolina AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 248: Tennessee AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 249: Tennessee AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 250: Tennessee AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 251: Tennessee AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 252: Tennessee AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 253: South Carolina AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 254: South Carolina AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 255: South Carolina AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 256: South Carolina AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 257: South Carolina AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 258: Alabama AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 259: Alabama AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 260: Alabama AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 261: Alabama AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 262: Alabama AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 263: Mississippi AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 264: Mississippi AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 265: Mississippi AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 266: Mississippi AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 267: Mississippi AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 268: Louisiana AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 269: Louisiana AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 270: Louisiana AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 271: Louisiana AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 272: Louisiana AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 273: Arkansas AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 274: Arkansas AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 275: Arkansas AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 276: Arkansas AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 277: Arkansas AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 278: Kentucky AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 279: Kentucky AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 280: Kentucky AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 281: Kentucky AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 282: Kentucky AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 283: Oklahoma AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 284: Oklahoma AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 285: Oklahoma AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 286: Oklahoma AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 287: Oklahoma AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 288: Virginia AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 289: Virginia AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 290: Virginia AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 291: Virginia AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 292: Virginia AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 293: Maryland AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 294: Maryland AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 295: Maryland AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 296: Maryland AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 297: Maryland AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 298: West Virginia AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 299: West Virginia AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 300: West Virginia AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 301: West Virginia AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 302: West Virginia AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 303: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market: Regional Overview and Trends
TABLE 304: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market: Key Manufacturers, AI Developers and Procurement Ecosystem
TABLE 305: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 306: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 307: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 308: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 309: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 310: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 311: Illinois AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 312: Illinois AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 313: Illinois AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 314: Illinois AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 315: Illinois AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 316: Ohio AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 317: Ohio AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 318: Ohio AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 319: Ohio AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 320: Ohio AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 321: Michigan AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 322: Michigan AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 323: Michigan AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 324: Michigan AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 325: Michigan AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 326: Minnesota AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 327: Minnesota AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 328: Minnesota AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 329: Minnesota AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 330: Minnesota AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 331: Indiana AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 332: Indiana AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 333: Indiana AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 334: Indiana AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 335: Indiana AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 336: Wisconsin AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 337: Wisconsin AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 338: Wisconsin AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 339: Wisconsin AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 340: Wisconsin AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 341: Missouri AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 342: Missouri AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 343: Missouri AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 344: Missouri AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 345: Missouri AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 346: Iowa AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 347: Iowa AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 348: Iowa AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 349: Iowa AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 350: Iowa AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 351: Kansas AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 352: Kansas AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 353: Kansas AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 354: Kansas AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 355: Kansas AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 356: Nebraska AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 357: Nebraska AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 358: Nebraska AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 359: Nebraska AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 360: Nebraska AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 361: North Dakota AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 362: North Dakota AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 363: North Dakota AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 364: North Dakota AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 365: North Dakota AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 366: South Dakota AI-Enabled Cardiovascular Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 367: South Dakota AI-Enabled Cardiovascular Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 368: South Dakota AI-Enabled Cardiovascular Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 369: South Dakota AI-Enabled Cardiovascular Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 370: South Dakota AI-Enabled Cardiovascular Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 371: U.S. AI-Enabled Cardiovascular Devices Market: Competitive Landscape Snapshot, 2025
TABLE 372: U.S. AI-Enabled Cardiovascular Devices Market: Key Company Market Share Analysis, 2025
TABLE 373: U.S. AI-Enabled Cardiovascular Devices Market: Company Positioning Matrix
TABLE 374: U.S. AI-Enabled Cardiovascular Devices Market: AI Portfolio, Regulatory and Clinical Evidence Benchmarking of Key Players
TABLE 375: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 376: GE HealthCare: Company Profile
TABLE 377: Siemens Healthineers: Company Profile
TABLE 378: Philips: Company Profile
TABLE 379: Abbott Laboratories: Company Profile
TABLE 380: Medtronic: Company Profile
TABLE 381: Boston Scientific Corporation: Company Profile
TABLE 382: Johnson & Johnson MedTech: Company Profile
TABLE 383: Edwards Lifesciences: Company Profile
TABLE 384: iRhythm Technologies: Company Profile
TABLE 385: HeartFlow: Company Profile
TABLE 386: Cleerly: Company Profile
TABLE 387: Viz.ai: Company Profile
TABLE 388: Eko Health: Company Profile
TABLE 389: AliveCor: Company Profile
TABLE 390: Tempus AI: Company Profile
TABLE 391: Anumana: Company Profile
TABLE 392: Ultromics: Company Profile
TABLE 393: Us2.ai: Company Profile
TABLE 394: Elucid: Company Profile
TABLE 395: CathWorks: Company Profile
TABLE 396: Circle Cardiovascular Imaging: Company Profile
TABLE 397: Artrya: Company Profile
TABLE 398: iCardio.ai: Company Profile
TABLE 399: MyCardium AI: Company Profile
TABLE 400: Murj: Company Profile
TABLE 401: U.S. AI-Enabled Cardiovascular Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 402: U.S. AI-Enabled Cardiovascular Devices Market: Disruptive Technologies Impact Matrix
TABLE 403: U.S. AI-Enabled Cardiovascular Devices Market: Emerging Business and Commercialization Trends
TABLE 404: U.S. AI-Enabled Cardiovascular Devices Market: Business Opportunities for Startups and Existing Players
TABLE 405: U.S. AI-Enabled Cardiovascular Devices Market: Investment Prioritization Matrix
TABLE 406: U.S. AI-Enabled Cardiovascular Devices Market: Market Consolidation, Partnership and Acquisition Outlook
TABLE 407: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations for Cardiovascular Device and Imaging Manufacturers
TABLE 408: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations for Hospitals, Health Systems and Cardiac Service Lines
TABLE 409: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations for Investors, Private Equity and Venture Capital Firms
TABLE 410: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations for AI Algorithm and Clinical Software Developers
TABLE 411: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations for Distributors, Cloud Providers and Technology Integrators
TABLE 412: U.S. AI-Enabled Cardiovascular Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 413: U.S. AI-Enabled Cardiovascular Devices Market: U.S. Go-to-Market and Reimbursement Strategy Considerations
TABLE 414: U.S. AI-Enabled Cardiovascular Devices Market: Product Positioning, Evidence Generation and Portfolio Expansion Guidance
TABLE 415: U.S. AI-Enabled Cardiovascular Devices Market: Scope Limitation
TABLE 416: U.S. AI-Enabled Cardiovascular Devices Market: Data Use Limitation
TABLE 417: U.S. AI-Enabled Cardiovascular Devices Market: Forecasting Limitation
TABLE 418: U.S. AI-Enabled Cardiovascular Devices Market: AI Technology and Regulatory Change Limitation
TABLE 419: U.S. AI-Enabled Cardiovascular Devices Market: Legal Disclaimer
TABLE 420: U.S. AI-Enabled Cardiovascular Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. AI-Enabled Cardiovascular Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: AI Medical Device Classification and Revenue Attribution Framework
FIGURE 4: Value Chain Analysis
FIGURE 5: Supply Chain Analysis
FIGURE 6: PESTEL Analysis
FIGURE 7: Porter’s Five Forces Analysis
FIGURE 8: Market Attractiveness Analysis
FIGURE 9: Market Dynamics
FIGURE 10: AI-Enabled Cardiovascular Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Hospital Enterprise AI Procurement and Governance Framework
FIGURE 13: Algorithm Validation, Model Drift and Post-Market Performance Lifecycle
FIGURE 14: U.S. AI-Enabled Cardiovascular Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 15: U.S. AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 16: U.S. AI-Enabled Cardiovascular Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 17: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 18: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 19: AI-Enabled Cardiovascular Imaging and Visualization Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: AI-ECG and Electrophysiology Analytics Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: AI-Enabled Wearable and Ambulatory Cardiac Monitoring Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: AI-Assisted Interventional and Procedural Cardiovascular Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: AI-Integrated Implantable and Therapeutic Cardiovascular Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 25: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Coronary Artery Disease and Ischemia Assessment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Arrhythmia Detection and Rhythm Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Heart Failure Detection and Longitudinal Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Structural Heart and Valvular Disease Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Preventive Cardiology, Vascular Disease and Stroke Risk Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 32: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Hospitals and Integrated Delivery Networks Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Academic Medical Centers and Cardiac Specialty Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Cardiology Practices and Diagnostic Imaging Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Ambulatory Surgery Centers and Office-Based Laboratories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: Home Healthcare, Remote Monitoring and Virtual Cardiology Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 39: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Machine Learning and Deep Learning Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Computer Vision and Automated Image Quantification Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: AI Signal Processing and Digital Biomarkers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Predictive Analytics and Clinical Decision Support Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Cloud-Connected, Edge AI and Sensor Fusion Platforms Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 46: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: Direct Hospital and Health System Enterprise Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: OEM-Embedded and Capital Equipment Platform Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Cloud Subscription, Software-as-a-Medical-Device and Per-Analysis Licensing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Group Purchasing Organization, Distributor and Technology Integrator Channels Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Payer-Provider, Remote Monitoring and Population Health Program Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 53: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 54: West Region U.S. AI-Enabled Cardiovascular Devices Market Share and Leading Players, 2025
FIGURE 55: West Region Market Share Analysis by State, 2025
FIGURE 56: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 57: California AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: Washington AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Arizona AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Colorado AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Oregon AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Utah AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Nevada AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: New Mexico AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Idaho AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Montana AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Wyoming AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Alaska AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Hawaii AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Northeast Region U.S. AI-Enabled Cardiovascular Devices Market Share and Leading Players, 2025
FIGURE 71: Northeast Region Market Share Analysis by State, 2025
FIGURE 72: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: New York AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Massachusetts AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: New Jersey AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Pennsylvania AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Connecticut AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Maine AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Vermont AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Hampshire AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Rhode Island AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Delaware AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: South Region U.S. AI-Enabled Cardiovascular Devices Market Share and Leading Players, 2025
FIGURE 84: South Region Market Share Analysis by State, 2025
FIGURE 85: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Texas AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Florida AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Georgia AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: North Carolina AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Tennessee AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: South Carolina AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Alabama AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Mississippi AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Louisiana AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Arkansas AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Kentucky AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Oklahoma AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Virginia AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Maryland AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: West Virginia AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Midwest Region U.S. AI-Enabled Cardiovascular Devices Market Share and Leading Players, 2025
FIGURE 102: Midwest Region Market Share Analysis by State, 2025
FIGURE 103: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Illinois AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Ohio AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Michigan AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Minnesota AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Indiana AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Wisconsin AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Missouri AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Iowa AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Kansas AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Nebraska AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: North Dakota AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: South Dakota AI-Enabled Cardiovascular Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 117: Company Positioning Matrix
FIGURE 118: Key Player AI Portfolio, Regulatory and Clinical Evidence Benchmarking
FIGURE 119: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 120: AI-Enabled Cardiovascular Device Innovation Roadmap
FIGURE 121: Multimodal Cardiovascular AI and Foundation Models Roadmap
FIGURE 122: Predictive ECG and Population Screening Adoption Roadmap
FIGURE 123: Autonomous Echocardiography and Automated Image Acquisition Opportunity Map
FIGURE 124: AI-Enabled Coronary Plaque Analysis and Procedure Planning Roadmap
FIGURE 125: Closed-Loop Implantable Device Intelligence and Remote Monitoring Roadmap
FIGURE 126: Future Market Scenario Analysis, 2026–2035
FIGURE 127: Disruptive Technologies Impact Matrix
FIGURE 128: Emerging Business and Commercialization Trends Matrix
FIGURE 129: Investment Prioritization Matrix
FIGURE 130: Strategic Growth Roadmap for U.S. AI-Enabled Cardiovascular Device Companies
FIGURE 131: U.S. Go-to-Market and Reimbursement Strategy Framework
FIGURE 132: Evidence Generation, Product Positioning and Portfolio Expansion Framework
FIGURE 133: Report Scope and Disclaimer Framework